BRAFV600E: implications for carcinogenesis and molecular therapy.
AffiliationDepartment of Histopathology, Trinity College, Sir Patrick Dun Research, Laboratory, Pathology Building, St. James' Hospital, Dublin 8, Ireland., firstname.lastname@example.org
Cell Transformation, Neoplastic/*genetics
Extracellular Signal-Regulated MAP Kinases/genetics/metabolism
Mitogen-Activated Protein Kinases/*genetics/metabolism
*Molecular Targeted Therapy
Proto-Oncogene Proteins B-raf/*genetics
MetadataShow full item record
CitationMol Cancer Ther. 2011 Mar;10(3):385-94.
JournalMolecular cancer therapeutics
AbstractThe mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is frequently mutated in human cancer. This pathway consists of a small GTP protein of the RAS family that is activated in response to extracellular signaling to recruit a member of the RAF kinase family to the cell membrane. Active RAF signals through MAP/ERK kinase to activate ERK and its downstream effectors to regulate a wide range of biological activities including cell differentiation, proliferation, senescence, and survival. Mutations in the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF) isoform of the RAF kinase or KRAS isoform of the RAS protein are found as activating mutations in approximately 30% of all human cancers. The BRAF pathway has become a target of interest for molecular therapy, with promising results emerging from clinical trials. Here, the role of the most common BRAF mutation BRAF(V600E) in human carcinogenesis is investigated through a review of the literature, with specific focus on its role in melanoma, colorectal, and thyroid cancers and its potential as a therapeutic target.
- Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
- Authors: Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N
- Issue date: 2007 Mar
- C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
- Authors: Karreth FA, DeNicola GM, Winter SP, Tuveson DA
- Issue date: 2009 Nov 13
- Therapeutic strategies for inhibiting oncogenic BRAF signaling.
- Authors: Halilovic E, Solit DB
- Issue date: 2008 Aug
- RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
- Authors: Fan F, Feng L, He J, Wang X, Jiang X, Zhang Y, Wang Z, Chen Y
- Issue date: 2008 Jun
- Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
- Authors: Yang R, Piperdi S, Gorlick R
- Issue date: 2008 Oct 15